Belite Bio, Inc BLTE

Set alert

Price alert · BLTE

All alert types
154.80 USD +1.13 +0.74%

As of Nov 3, 1:11 PM ET

Bid
154.30 × 2
Ask
155.10 × 2
153.41 Day range 157.47
102.00 52-week range 200.00
YTD
-3.23%
1 year
+37.72%
Open
156.01
Prev close
153.67
Mkt cap
6.24B
Vol
101.06K
Avg vol
177.40K
EPS
-2.74
P/E
0.00
Div yield
0.00%
More statistics
Low
153.41
High
157.47
Forward P/E
68.00
Beta
-1.19
Short ratio
7.77
Inst. own
24.27%
Dividend
0.00
Ex-div date
Earnings
Nov 9, 2026
50-d avg
161.47
200-d avg
160.36
1y target
227.44

3M chart

Chart tools
Interval

Events in this range
  • Aug 12, 2026Earnings: -0.7; estimate -0.73; surprise 4.11%
  • Aug 14, 2026Rating: Cantor Fitzgerald · Overweight → Overweight
  • Aug 14, 2026Rating: Morgan Stanley · Overweight → Overweight
  • Sep 4, 2026Rating: Canaccord Genuity · — → Buy
  • Sep 8, 2026Rating: HC Wainwright & Co. · Buy → Buy
  • Sep 9, 2026Rating: Mizuho · Outperform → Outperform
  • Oct 15, 2026Rating: HC Wainwright & Co. · Buy → Buy
Signals (16)
NameDateAgo
MACD: Buy SignalOct 29, 20265 days ago
SMA: BearishOct 1, 20261 month ago
SMA: BearishOct 1, 20261 month ago
SMA: BullishSep 30, 20261 month ago
SMA: BearishSep 25, 20261 month ago
MACD: Sell SignalSep 16, 20261 month ago
MACD: Buy SignalSep 4, 20262 months ago
RSI: OverboughtSep 4, 20262 months ago
SMA: BullishSep 2, 20262 months ago
SMA: BullishSep 1, 20262 months ago
SMA: BearishAug 28, 20262 months ago
SMA: BearishAug 26, 20262 months ago
SMA: BullishAug 25, 20262 months ago
SMA: BearishAug 24, 20262 months ago
MACD: Sell SignalAug 18, 20262 months ago
RSI: OverboughtAug 11, 20262 months ago

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 227.44 +46.9% upside
Target (low)
185.00
Target (mean)
227.44
Target (high)
303.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
  • Strong buy2
  • Buy7
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 9
  • 1 month ago 9
  • 2 months ago 8

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

BLTE analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.76875-1.16 – -0.52-0.65-18.3%00.0%8
Next quarter-0.90375-1.43 – -0.51-0.70-29.1%00.0%8
Current year-2.94-3.97 – -1.30-2.31-27.1%00.0%8
Next year2.26-2.87 – 15.37-2.94+177.0%274.23M0.0%8

Upgrades and downgrades

The latest rating changes

BLTE analyst upgrades and downgrades
DateFirmActionFromTo
Oct 15, 2026HC Wainwright & Co.ReiteratedBuyBuy
Sep 9, 2026MizuhoMaintainedOutperformOutperform
Sep 8, 2026HC Wainwright & Co.MaintainedBuyBuy
Sep 4, 2026Canaccord GenuityInitiated—Buy
Aug 14, 2026Morgan StanleyMaintainedOverweightOverweight
Aug 14, 2026Cantor FitzgeraldMaintainedOverweightOverweight
Aug 12, 2026HC Wainwright & Co.MaintainedBuyBuy
Jun 15, 2026HC Wainwright & Co.ReiteratedBuyBuy
May 26, 2026MizuhoMaintainedOutperformOutperform
May 21, 2026HC Wainwright & Co.ReiteratedBuyBuy
Apr 22, 2026HC Wainwright & Co.ReiteratedBuyBuy
Apr 13, 2026HC Wainwright & Co.ReiteratedBuyBuy
Mar 3, 2026HC Wainwright & Co.MaintainedBuyBuy
Mar 3, 2026Morgan StanleyMaintainedOverweightOverweight
Mar 3, 2026Cantor FitzgeraldMaintainedOverweightOverweight
Jan 28, 2026HC Wainwright & Co.ReiteratedBuyBuy
Jan 26, 2026B of A SecuritiesInitiated—Buy
Jan 6, 2026Morgan StanleyInitiated—Overweight
Dec 2, 2025MizuhoUpgradeNeutralOutperform
Dec 1, 2025HC Wainwright & Co.MaintainedBuyBuy
Nov 20, 2025MizuhoInitiated—Neutral
Oct 31, 2025BenchmarkMaintainedBuyBuy
Sep 15, 2025HC Wainwright & Co.MaintainedBuyBuy
Jul 3, 2025HC Wainwright & Co.ReiteratedBuyBuy
May 15, 2025Cantor FitzgeraldReiteratedOverweightOverweight
May 15, 2025HC Wainwright & Co.ReiteratedBuyBuy
Mar 26, 2025BenchmarkReiteratedBuyBuy
Mar 18, 2025Cantor FitzgeraldReiteratedOverweightOverweight
Mar 18, 2025HC Wainwright & Co.ReiteratedBuyBuy
Jan 21, 2025BenchmarkMaintainedBuyBuy